AbbVie Stock: I Was So Wrong, But This Is Way Too Fast (NYSE:ABBV)

JHVEPhoto I’ve underestimated biopharma company AbbVie Inc.’s (NYSE:ABBV) ability to overcome the near- and medium-term headwinds from Humira’s LOE. I assessed that the risk/reward of ABBV was well-balanced in my previous update in late November 2023. However, that Hold/Neutral thesis has proved to be too cautious. I had anticipated selling pressure to intensify, potentially leading…

Read More

AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript

AbbVie Inc. (NYSE:ABBV) Q4 2023 Earnings Conference Call February 2, 2024 9:00 AM ET Company Participants Liz Shea – Vice President of Investor Relations Rick Gonzalez – Chairman of the Board & Chief Executive Officer Rob Michael – President & Chief Operating Officer Jeff Stewart – Executive Vice President & Chief Commercial Officer Carrie Strom…

Read More

AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference

AbbVie Inc. (NYSE:ABBV) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 11:15 AM ET Company Participants Rob Michael – President and Chief Operating Officer Jeff Stewart – Chief Commercial Officer Roopal Thakkar – Chief Medical Officer Conference Call Participants Chris Schott – J.P.Morgan Chris Schott Good morning, everybody. I’m Chris Schott at J.P.Morgan, and…

Read More

AbbVie: Balance Is Everything (NYSE:ABBV)

Hailshadow The Decline of Humira For the first seven years of AbbVie’s (NYSE:ABBV) existence as a public company, its top selling drug Humira made up over 60% of the company’s total sales on average. By some accounts, based on cumulative sales since its launch in 2003, Humira has been the top selling drug of all…

Read More